Medesis Pharma S.A.

Regulatory Filings • Dec 2, 2021

Montpellier, December 2, 2021 - 8:00 a.m. - Medesis Pharma, a pharmaceutical biotechnology company developing drug candidates from its proprietary technology for the administration of active ingredients in nano micelles by the buccal route Aonys®, announces its participation in the 3rd congress on therapy gene for neurological disorders which takes place from December 6 to 9 in Boston (United States).

The 3rd Gene Therapy for Neurological Diseases Conference will host scientists from industry, preclinical, translational and clinical research to share, learn and network with the common goal of safely and successfully delivering gene therapies to central nervous system.

Attending this Congress are over 300 experts in gene therapy for neurological disorders from leading pharmaceutical and biotechnology companies, including Novartis, 4D Molecular Therapeutics, Prevail Therapeutics, Astellas, Sio Gene Therapies, Voyager Therapeutics, SwanBio and many more.

Ms. Solène Guilliot, Director of Medical Affairs and Clinical Developments at Medesis Pharma will present a poster describing pharmacokinetics and pharmacological data supporting the potential of Aonys® buccal drug delivery technology to deliver unmodified siRNAs for the treatment of neurodegenerative diseases with ubiquitarian overexpression of a gene and in particular its potential application in Huntington's disease.

Medesis Pharma's proprietary technology, Aonys®, is an assembly of lipid components that spontaneously self-structure into a "water-in-oil" microemulsion. Aonys® allows the administration of water-soluble pharmaceutical active ingredients. The product is deposited on the mucosa of the mouth and then transported by lipoproteins and released directly into the cytoplasm of cells throughout the membrane using cell lipoprotein receptors, with crossing of the Blood-Brain Barrier (BBB). Studies on native siRNAs encapsulated in Aonys® have demonstrated crossing of BBB, intracellular delivery, efficient reduction of the target gene, and associated phenotypic results in mouse models.

More information about the congress: https://genetherapy-neurological.com/

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood–brain barrier (BBB). This innovative approach is being applied for future drugs to treat major diseases that do not have effective treatments: Alzheimer's Disease, Huntington's Disease, certain resistant cancers and severe respiratory inflammations such as those linked to COVID-19. Medesis Pharma is also developing dedicated treatments for people irradiated following a civil or military nuclear accident.

Medesis Pharma, a French biopharmaceutical company based near Montpellier, has a track record of 15 scientific publications, holds ten patents, reflecting 17 years of research, and is focused specifically on four projects that are moving into Clinical Phase II for neurodegenerative diseases and the treatment of Covid-19. Building on its world-renowned positions, Medesis Pharma is also working on new applications for its technology in partnership with public research laboratories (CNRS, CEA, IRBA), major teaching hospital centers in France, Canada and the United States, as well as private structures such as Transgene

Medesis Pharma's shares are listed on Euronext Growth Paris (FR0010844464 – ALMDP).

For more informations : www.medesispharma.com

MEDESIS PHARMA Tessa Olivato

Tel: +33 4 67 03 03 96 contact@medesispharma.com

CALYPTUS Marie Calleux Tel : +33 1 53 65 68 66 medesispharma@calyptus.net